Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2025-12-26 @ 5:42 PM
Study NCT ID:
NCT00383760
Status:
COMPLETED
Last Update Posted:
2017-10-20
First Post:
2006-09-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-08
Start Date Type:
None
Primary Completion Date:
2011-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-07
Completion Date Type:
ACTUAL
First Submit Date:
2006-09-29
First Submit QC Date:
None
Study First Post Date:
2006-10-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-04-18
Results First Submit QC Date:
None
Results First Post Date:
2016-12-09
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-09-19
Last Update Post Date:
2017-10-20
Last Update Post Date Type:
ACTUAL